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INTRODUCTION
Diabetes is a metabolic disease characterized by persistent hy-
perglycemia caused by dysfunction of insulin secretion and dete-
riorated insulin resistance. Long-standing persistent hyperglycemia
causes various diabetic complications, such as nephropathy, retino-
pathy, neuropathy, and various macrovascular diseases. Thus, the
control of blood glucose levels is essential for diabetes therapy.
Most conventional diabetes therapies target insulin. However,
the emergence of incretin-related drugs, such as dipeptidyl pepti-
dase-4 inhibitors, which reduce plasma glucagon and are thought
to contribute to lowering blood glucose, elucidated that the mecha-
nism of diabetes onset is closely related to glucagon (1-3). It was
reported that glucagon suppression in type 1 diabetic patients per-
mits better control of hyperglycemia with reduced doses of insulin
(4). Moreover, recent reports showed that glucagon suppression
induced by glucagon- like peptide-1 (GLP-1) and GLP-1 receptor
agonist administration ameliorates blood glucose levels in type 1
diabetic patients without residual insulin secretion (5). Thus, glu-
cagon suppression might play a key role in glucose homeostasis
and the “glucagonocentric hypothesis” was proposed, which states
that antecedent α -cell failure and inhibition of glucagon secretion
are responsible for diabetes progression (6, 7). This hypothesis was
further supported by many studies using glucagon receptor gene
knockout mice and anti -glucagon receptor antibody (8, 9).
Protein kinase C (PKC) is a serine/threonine kinase and it con-
sists of 11 isoforms : conventional PKC (α, β, and γ), novel PKC
(δ, ε, η, and θ), and atypical PKC (ζ and ι/λ) (10, 11). It was re-
ported that activation of PKC by phorbol 12-myristate 13-acetate
(PMA) stimulated glucagon secretion from mouse and human
pancreatic islets, which was abolished by treatment with PKC in-
hibitors (12-14). However, in these studies, the PKC isozyme in-
volved in the PMA-induced glucagon secretion was not identified.
It was also reported that PKCδ was involved in the onset and pro-
gression of diabetes, and the inhibition of PKCδ expression or its
activation prevents β -cell dysfunction and apoptosis, thereby im-
proving diabetic symptoms (15, 16). However, the effect of PKCδ
on the function of α -cells has not yet been elucidated.
We have demonstrated that PKCδ signaling is involved in PMA-
induced upregulation of histamine H1 receptor (H1R) gene ex-
pression in HeLa cells and compounds, including quercetin and
(-) -maackiain, suppressed H1R gene expression through the in-
hibition of PKCδ signaling (17-19). Thus, suppression of PKCδ
signaling by these compounds could improve diabetic symptoms
and help to further elucidate the mechanisms underlying these
actions to better understand the role of PKCδ signaling in diabetes
onset and progression. In fact, it was demonstrated that quercetin
ameliorated the symptoms of streptozotocin (STZ)- induced dia-
betes (20, 21). However, in these studies, antioxidant activity was
thought to be the mechanism of action of quercetin and the effect
of PKCδ signaling on diabetic symptoms was not addressed.
Here we elucidated the involvement of PKCδ signaling in dia-
betes onset and progression. We found that PKCδ is activated in
α -cells after the onset of diabetes using STZ- induced diabetic
model mice. We also showed that activation of PKCδ signaling
augmented glucagon secretion and PKCδ signaling inhibitors
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suppressed it in isolated islets from mice.
Materials and Methods
Materials
Streptozotocin, PMA, Histopaque1077, Histopaque1199, rot-
tlerin, cOmplete Mini, and PhosSTOP phosphatase inhibitor cock-
tail were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Quercetin was from Wako Pure Chemical (Osaka). Ro-31-8220
and Go6976 were fromMerck Millipore (Billerica, Ma, USA). Celas-
trol was from Cayman Chemical (Ann Arbor, MI, USA). RPMI-
1640 medium and HBSS were from Invitrogen (Carlsbad, CA,
USA) and Thermo Fisher Scientific (Waltham, MA, USA), respec-
tively. Collagenase type IV was from Worthington Biochemical
Corporation (Lakewood, NJ, USA). A glucagon assay kit was from
Cisbio Bioassays (Codolet, France). Mouse insulin assay kit was
from Morinaga Institute of Biological Science (Yokohama). RNeasy
Mini Kit was from QIAGEN (Tokyo). PrimeScript RT Reagent Kit,
and Premix ExTaq were from Takara Bio Inc. (Kyoto). Smear Gell
was from GenoStaff (Tokyo). DeadEnd Fluorometric TUNEL Sys-
tem and RQ1 RNase-Free DNase were from Promega (Madison,
WI, USA). All other chemicals were of analytical grade.
Preparation of STZ-induced diabetic model mice
Male C57BL/6JJmsSlc mice (8-15-week-old, Japan SLC,
Hamamatsu) were housed in a room at a constant temperature of
252 and humidity of 5510% under a 12-h light/dark cycle
with free access to food and water. Mice were intraperitoneally
injected with STZ (200 mg/kg) freshly dissolved in 0.1 M citrate
buffer (pH 4.5). Four days after STZ injection, blood glucose was
measured and mice with blood glucose levels300 mg/dl were
considered diabetic. Mice were divided into two groups : a control
group (n=5) and a STZ-treated group (n=15). After 6 weeks, no
mouse died. Experiments using similar conditions were previously
conducted, in which no mice died (7). All animal experiments were
approved by the Ethical Committee for Animal Studies of Tokushima
University School of Medicine.
Immunohistochemical analysis
Pancreatic tissues were fixed in 10% neutral buffered-formalin,
embedded in paraffin, and cut into 5 μm-thick sections. The sec-
tions were deparaffinized, blocked with 5% normal donkey serum
for 45 min, and stained with anti - insulin antibody (Abcam Japan,
Tokyo), anti -glucagon (C-18) antibody (Santa Cruz Biotechnology,
Santa Cruz, CA, USA), anti -PKCδ antibody (Cell Signaling Tech-
nology Japan, Tokyo), and anti -phospho-Tyr311 PKCδ antibody
(Cell Signaling). Antibodies and 4,6-diamidino-2-phenylindole
(DAPI) were diluted in Can Get Signal immunostain Solution A
(Toyobo, Osaka). The sections were observed using LSM510 con-
focal laser-scanning microscope (Carl Zeiss AG, Oberkochen,
Germany). RGB profile plots were detected using Image J image
processing software (http : //imagej.nih.gov/ij/).
Pancreatic islet isolation
Mice were anesthetized by the intraperitoneal injection of pen-
tobarbital. Then, the stomach and duodenum were removed and
placed to the right of the body cavity. The common bile duct was
clipped and collagenase IV solution (1.5 mg/ml) was injected into
the pancreatic duct using a stereoscopic microscope. The entire
pancreas was removed and placed in a 15-ml tube containing col-
lagenase IV solution and heated for 40 min at 37. HBSS solution
(1% bovine serum albumin (BSA), 100 IU/ml penicillin, 50 μg/ml
streptomycin) was added to the cell suspension and centrifuged at
1,200 rpm for 2 min. After the supernatant was discarded, Histopaque
solution (5 ml of Histopaque1077 and 6 ml of Histopaque1119) was
added to the cells and centrifuged at 1,200 rpm for 20 min. Then
the supernatant was transferred to a new 50-ml tube and 25 ml of
HBSS solution was added. The cell suspension was centrifuged at
1,500 rpm for 4 min, the precipitated cells were re-suspended in
HBSS solution, passed through a 100-μm cell strainer (BD Bi-
osciences, San Jose, CA, USA), and collected into a 10-cm dish.
Pancreatic islets were handpicked and cultured at 37 under a
humidified atmosphere of 5% CO2 and 95% air in islet medium
(RPMI-1640 medium containing 2.0 g/l NaHCO3, 10 mM HEPES
solution, 50 μM 2-mercaptoethanol, 1 mM sodium pyruvate, 10%
FBS, 100 IU/ml penicillin, and 50 μg/ml streptomycin) (22).
Glucagon and insulin secretion assay
Isolated islets were pre- incubated for 24 h in islet medium. After
pre- incubation, the medium was replaced with Krebs-Ringer modi-
fied buffer (KRB)-HEPES-BSA solution consisting of NaCl (120
mM), NaHCO3 (25 mM), KCl (4.7 mM), MgSO4 (1.2 mM), CaCl2
(2.5 mM), KH2PO4 (1.2 mM), HEPES (10 mM), BSA (1 mg/ml),
D-Glucose (2 mg/ml), penicillin (100 IU/ml), and streptomycin
(50 μg/ml) at pH 7.4. Three islets were transferred to a 1.5-ml tube
with 300 μl of KRB-HEPES-BSA solution (22) and then treated
with quercetin (15, 30, and 60 μM), rottlerin (1-10 μM), Ro-31-
8220 (1 μM), and Go6976 (1 μM), and celastrol (1 μM) for 1 h
before stimulation with 100 nM PMA. The supernatant was col-
lected 1 h after PMA stimulation and glucagon concentration was
determined using the HTRF glucagon assay kit. For the detection
of insulin secretion, three islets in a 1.5-ml tube with 300 μl of KRB-
HEPES-BSA solution were treated with quercetin (60 μM) for 1 h
before PMA stimulation. After 1 h stimulation with PMA, the super-
natant was collected and insulin concentration was determined
using the insulin assay kit.
Real-time quantitative RT-PCR
After 24 h pre- incubation in islet medium, 100 islets were trans-
ferred to a 24-well plate with 500 μl of the islet medium and treated
with quercetin (60 μM) for 4 h before PMA stimulation. Islets were
collected 4 h after PMA stimulation and total RNA was prepared.
Then, 5 μg of total RNA was reverse-transcribed to cDNA using the
PrimeScript RT Reagent Kit. Real - time PCR was conducted using
a GeneAmp 7300 sequence detection system (Applied Biosystems,
Foster City, CA, USA). Glucagon mRNA was determined using
TaqMan gene amplification primers and probes (Mm01269055_m1,
Applied Biosystems). To standardize the starting material, rodent
GAPDH mRNA was determined using TaqMan rodent GAPDH
Control Reagents (Applied Biosystems). Data are expressed as the
ratio of glucagon mRNA to GAPDH mRNA.
Apoptosis Assays
Isolated islets were pre- incubated for 24 h in islet medium. After
pre- incubation, the medium was replaced with new islet medium.
Islets were transferred to a 24-well plate with 500 μl of islet medium
and then treated with quercetin (60 μM) for 1 h before stimulation
with 100 nM PMA. Islets were collected using Smear Gell at 23 h
after PMA stimulation. Apoptosis was measured using the DeadEnd
Fluorometric TUNEL System. As a positive control, cells were
treated with RQ1 RNase-Free DNase as described in the manu-
facturer’s protocol. Sections were observed using LSM510 con-
focal laser-scanning microscope.
Immunoblot analysis
For immunoblot analysis, isolated islets from 8 mice were pre-
incubated for 24 h in islet medium. After pre- incubation, islets were
transferred to a 24-well plate with 500 μl of islet medium and then
treated with quercetin (60 μM) for 1 h before stimulation with
100 nM PMA. Islets were collected at 10 min after PMA stimulation
and then homogenized in 20 mM Tris-HCl, pH 7.5 containing
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100 mM NaCl, 0.5% Triton X-100, cOmplete Mini and PhosSTOP.
Whole cell lysates were prepared by sonication and 30 μg of each
protein was separated on a 10% SDS-PAGE gel. Immunoblot analy-
sis was conducted using primary antibodies (PKCδ (C-20), Santa
Cruz Biotechnology ; phospho-Tyr311 PKCδ ; β -actin). Proteins
were visualized with an Immobilon Western Chemiluminescent
HRP substrate (Merck Millipore).
Statistical analysis
Results are expressed as the meanSEM. Statistical analyses
were performed using analysis of variance with the Dunnett’s
test and t - test using GraphPad Prism software (GraphPad Soft-
ware Inc., La Jolla, CA, USA). P0.05 was considered statistically
significant.
RESULTS
Localization of PKCδ in islets after the onset of diabetes
Before STZ injection, β -cells, represented as insulin- immunore-
active cells, were observed throughout the islets of normal mice,
whereas α -cells, represented as glucagon- immunoreactive cells,
were localized in the penumbra of islets (Fig. 1A, control). After
STZ treatment for 4 days to induce diabetes, β -cells were elimi-
nated in the islets (Fig. 1A, 0 day). On the other hand, α -cells were
distributed throughout the islets (Fig. 1A, 0 day and 6 weeks).
Before STZ injection, PKCδ expression levels were low in the islets
(Fig. 1A, control). However, after the onset of STZ-induced diabe-
tes, PKCδ expression was increased (Fig. 1A). The localization of
PKCδ - immunoreactive cells was different from that of β -cells
(Fig. 1A and 1B) and was consistent with that of α -cells (Fig. 1A
and 1B). Next, we investigated the effect of STZ on the phospho-
rylation of PKCδ at Tyr311 that is crucial for its activation (11).
Phospho-Tyr311 PKCδ - immunoreactive cells increased after STZ
stimulation and co- localized with α -cells (Fig. 1C and 1D).
Effect of quercetin on glucagon secretion from isolated islets
Immunofluorescence studies showed that STZ-induced increase
in PKCδ expression and its activation in α -cells after the onset of
diabetes (Fig. 1) suggesting that PKCδ plays some physiological
roles in α -cells. PMA-induced PKCδ activation caused significant
increase in glucagon secretion from isolated islets (Fig. 2). Pre-
treatment with rottlerin, a PKCδ signaling inhibitor and Ro-31-8220,
a pan PKC inhibitor, significantly suppressed PMA-induced gluca-
gon secretion. However, Go6976, a Ca2+ -dependent PKC selective
inhibitor had no effect (Fig. 2). It was recently reported that rot-
tlerin also inhibited PKCθ another nPKC isoform, with IC50 of
1.6 μM and less than 3 μM of rottlerin selectively inhibited PKCθ
(23). PMA-induced glucagon secretion was not suppressed by less
than 2.5 μM of rottlerin, suggesting that PKCθ was not involved
in PMA-induced glucagon secretion (Fig. 2).
Previously, we reported that quercetin is a PKCδ signaling
(A) (B)
(C) (D)
Fig 1. Localization of PKCδ in pancreatic islets.
Pancreases were harvested on 0, 3, and 6 weeks after the onset of diabetes and subjected to immunofluorescence analysis. (A) Images of double
staining of insulin and PKCδ (a) and glucagon and PKCδ (b). (B) RGB profile plot of STZ 6 weeks insulin/PKCδ and glucagon/PKCδ. (C) Images of
double staining of insulin and phospho-PKCδ (a) and glucagon and phospho-PKCδ (b). (D) RGB profile plot of STZ 6 weeks insulin/phospho-PKCδ
and glucagon/phospho-PKCδ. Images were captured using a confocal laser scanning microscope. RGB profile plot was detected with Image J image
processing software. Scale bar : 50 μm












inhibitor (18). We also reported that heat shock protein 90 (Hsp90)
regulated PKCδ signaling in HeLa cells (24). Therefore, we inves-
tigated the effect of quercetin and Hsp90 inhibitors on PMA-in-
duced glucagon secretion. Quercetin suppressed the PMA-induced
increase in glucagon secretion (Fig. 2), while an Hsp90 inhibitor
celastrol had no effect, suggesting that Hsp90 is not involved in
glucagon secretion (Fig. 2). Quercetin itself showed no effect on
glucagon secretion, suggesting the effect of quercetin was not due
to its anti -oxidant activity. Treatment with PMA alone and PMA
with quercetin did not induce cell apoptosis (Fig. 3), suggesting
that suppression of glucagon secretion by quercetin was not due
to cell apoptosis.
It was reported that insulin regulates glucagon secretion (25).
So, we investigated whether PMA-induced glucagon secretion
from isolated islets was due to the effect of insulin secreted in
response to PMA. Stimulation with PMA increased insulin secre-
tion in isolated islets (Fig. 4). However, treatment with quercetin
had no effect on its secretion, suggesting that PMA-induced glu-
cagon secretion is not due to the effect of insulin. PMA and/or
quercetin did not show any effect on glucagon gene expression in
isolated islets (Fig. 5).
Effect of quercetin on Tyr311 phosphorylation of PKCδ in isolated
islets
As PKCδ is phosphorylated at Tyr311 upon activation (11), we in-
vestigated the effect of quercetin on PMA-induced Tyr311 phospho-
rylation of PKCδ in isolated islets. Quercetin suppressed PMA-
induced Tyr311 phosphorylation of PKCδ (Fig. 6). It was reported
that PKCδ was also activated by proteolytic cleavage, in which
PKCδ is cleaved by caspase-3 and released the 41-kDa catalytic
fragment (26). However, immunoblot analysis showed no prote-
olytic cleavage of PKCδ in response to PMA.
DISCUSSION
In the present study, we showed that PKCδ was activated in α -
cells after the onset and progression of STZ-induced diabetes.
We also showed that PMA-induced PKCδ activation augmented
glucagon secretion and inhibition of PKCδ signaling suppressed
PMA-induced glucagon secretion in isolated islets.
Fig 2. Effect of quercetin on glucagon secretion from pancreatic islets.
Isolated islets were pre - incubated for 24 h in islet medium. After pre - incubation, the medium was replaced with KRB-HEPES-BSA solution. Three
islets were transferred to a 1.5 -ml tube with 300 μl of KRB-HEPES-BSA solution and treated with quercetin (15, 30, and 60 μM), rottlerin (1 -10 μM),
Ro-31 -8220 (1 μM), Go6976 (1 μM), and celastrol (1 μM) for 1 h before PMA stimulation. Supernatant was collected 1 h after stimulation with 100 nM
PMA. Secreted glucagon was measured using a glucagon assay kit. Data are expressed as meansSEM. Control, n=18 ; 60 μM quercetin, n=4 ;
PMA, n=15 ; PMA+Ro-31 -8220, n=4 ; PMA+Go6976, n=3 ; PMA+10 μM rottlerin, n=3 ; PMA+5 μM rottlerin, n=4 ; PMA+2.5 μM rottlerin, n=4 ;
PMA+1 μM rottlerin, n=4 ; PMA+celastrol, n=3 ; PMA+60 μM quercetin, n=9 ; PMA+30 μM quercetin, n=4 ; PMA+15 μM quercetin, n=4. ***p
0.001 vs. control ; ##p0.01, #p0.05 vs. PMA.
Fig. 3. Assessment of apoptosis by TUNEL staining.
Isolated islets were pre - incubated for 24 h in islet medium. After pre -
incubation, the medium was replaced with new islet medium. Islets were
transferred to a 24-well plate with 500 μl of islet medium and then treated
with quercetin (60 μM) for 1 h before stimulation with 100 nM PMA.
Islets were collected using Smear Gell at 23 h after PMA stimulation.
Images of double staining of fluorescein-12 -dUTP and propidium iodide.
As a positive control, cells were treated with RQ1 RNase-Free DNase as
described in the manufacturer’s protocol. Sections were observed using
a LSM510 confocal laser scanning microscope. Scale bar : 100 μm
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Immunohistochemical studies showed that STZ treatment re-
sulted in an increase in the abundance of α -cells concurrent with
a decrease in β -cells. Quantification analyses of the islet area re-
vealed that the β -cell area was significantly decreased after the
onset of diabetes, while the α -cell area tended to increase just after
the onset of diabetes and was significantly increased at 6 weeks
(data not shown). These results suggest that the α -cell mass gradu-
ally increased with time after the onset of STZ-induced diabetes
and may be involved in the progression of diabetic symptoms. Simi-
lar results were observed in pancreas-specific Forkhead box O1
(FoxO1) transgenic mice, which also developed diabetes (27). In
addition, a recent study reported that FoxO1 downregulation re-
sulting from hyperglycemia contributed to the dedifferentiation of
β -cells and the increased number of α -cells (28). Immunohisto-
chemical studies also showed an increase in PKCδ expression in
islets of STZ-induced diabetic mice, although its expression was
low before induction of diabetes. Double staining studies revealed
that PKCδ localization was virtually consistent with that of gluca-
gon, but not insulin. The data suggest that the increase in PKCδ
observed after STZ treatment is due to increased α -cell mass to
some extent (Fig. 1). However, the fluorescence intensity of PKCδ
was increased after STZ treatment, suggesting the PKCδ was in-
duced in response to STZ stimulation. The fluorescence intensity
of phospho-PKCδ was also increased in response to STZ stimu-
lation. Because of the different conditions to detect immunoreac-
tivities for total and phospho-PKCδ, we could not compare the
amount by means of fluorescence intensity. In addition, activation
of PKCδ (i.e. Tyr311 phosphorylation) is not always concomitant
with an increase in total PKCδ expression. Therefore, we consider
that the increase in phospho-PKCδ observed after STZ treatment
was not simply due to increased α -cell mass, but rather activation
of PKCδ in response to STZ stimulation and that PKCδ plays an
unknown pathophysiological role in α -cells of STZ-induced dia-
betic mice.
Several studies have reported the involvement of PKCδ in the
pathogenesis of diabetes and that PKCδ activation induced β -cell
apoptosis (13-16). PKCδ is a major contributor to hepatic insulin
resistance (29, 30). These reports focused on the effect of PKCδ on
β -cell function and insulin signaling because β -cell dysregulation
and insulin resistance are considered major factors in the onset of
diabetes (31, 32). However, recent accumulating evidence suggests
that dysregulation of glucagon secretion can also induce hypergly-
cemia, which is ameliorated by inhibition of glucagon function
(6-9). Moreover, it was reported that treatment with high glucose
increased glucagon secretion from isolated islets and PKC is in-
volved in this event, although the responsible PKC isozyme was not
identified (12-14). Our data demonstrate that PKCδ signaling is
responsible for the PMA-induced augmentation of glucagon secre-
tion in the isolated islets. We failed to detect PKCδ activation (i.e.
Tyr311 phosphorylation) in the pancreas. However, we observed
an increase in PKCδ - and phospho-Tyr311 PKCδ - immunoreactive
cells in glomeruli in response to STZ stimulation (Mizuguchi et al.
unpublished results). We confirmed this finding by immunoblot
analysis using the glomeruli of STZ-treated diabetic mice, in which
phosphorylation of PKCδ Tyr311 was increased in the glomerular
mesangial cells (Mizuguchi et al. unpublished results). So, our
data suggest that hyperglycemia caused by STZ treatment could
activate PKCδ. In this study, we used rottlerin as a PKCδ selective
inhibitor, although it was reported that rottlerin had a number of
non-PKCδ - related effects (33). Rottlerin has been used to confirm
the possible role of PKCδ isoform in several signaling pathways.
Moreover, the results obtained with rottlerin were compatible with
those obtained utilizing more selective approaches to inhibit PKCδ
in a previous report (17). It was recently reported rottlerin also
inhibited PKCθ (23). However, our data indicates that PKCθ is not
involved PMA-induced glucagon secretion. Together with these
findings, we believe that rottlerin is still accepted as a PKCδ inhibi-
tor, although rottlerin is reported to have a number of non-PKCδ -
related effects.
Quercetin is a well -characterized flavonoid and abundantly found
in tea, onions, mulberry, and manyfruits (34). High oxidative stress
due to persistent and chronic hyperglycemia is a hallmark of dia-
betes and promotes the pathogenesis and progression of tissue























Fig. 4. Effect of quercetin on insulin secretion from pancreatic islets.
Isolated islets were pre - incubated for 24 h in islet medium. After pre -
incubation, the medium was replaced with new islet medium. Three is-
lets were transferred to a 1.5 -ml tube with 300 μl of KRB-HEPES-BSA
solution and then treated with quercetin (60 μM) for 1 h before stimu-
lation with 100 nM PMA. The supernatant was collected 1 h after PMA
stimulation for the measurement of insulin concentration using an in-























Fig 5. Effect of quercetin on glucagon gene expression in pancreatic
islets.
Isolated islets were pre - incubated for 24 h in islet medium. After pre -
incubation, the medium was replaced with new islet medium and 100
islets were transferred to a 24-well plate with 500 μl of islet medium and
then treated with quercetin (60 μM) for 4 h before stimulation with 100
nM PMA. Islets were collected 4 h after PMA stimulation. Glucagon
mRNA was determined by real - time quantitative RT-PCR. Data are ex-
pressed as meansSEM (n=3).
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are thought to be useful to ameliorate the symptoms of STZ-induced
diabetes. In fact, several reports demonstrated the antidiabetic
effects of quercetin. For example, quercetin treatment significantly
decreased blood glucose levels in STZ-induced rats (20). It was
also reported that quercetin is not only effective against insulin
sensitivity, but also protects β -cells (21). However, the effect of
quercetin on α -cell function has not yet been reported. We showed
that treatment with PMA significantly increased glucagon secre-
tion from isolated islets and quercetin treatment suppressed the
PMA-induced increase in glucagon secretion in α -cells. We re-
ported that quercetin suppressed PMA-induced Tyr311 phospho-
rylation of PKCδ in HeLa cells (17). In the present study, we showed
that quercetin also suppressed PMA-induced Tyr311 phosphorylation
of PKCδ in isolated islets. Quercetin itself had no effect on gluca-
gon secretion in isolated islets. Also, quercetin did not suppress
PMA-induced insulin secretion in isolated islets. Furthermore, im-
munofluorescence analyses showed that PKCδ was expressed and
activated in α -cells in response to PMA stimulation. Together with
these findings, we consider that the suppressive effect of quercetin
on glucagon secretion is not due to its anti -oxidative effect, but
rather the suppression of PKCδ activation.
In conclusion, our data suggest that PKCδ signaling is activated
in α -cells after the onset of diabetes, which augments glucagon
release, resulting in hyperglycemia and progression of diabetic
symptoms. These data also suggest that the suppression of PKCδ
signaling could reduce excessive glucagon secretion in diabetes
and ameliorate symptoms. A detailed elucidation of the signaling
pathway underlying PKCδ activation and enhanced glucagon se-
cretion could help to development of drugs targeting PKCδ sig-
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Fig. 6. Effect of quercetin on PMA-induced Tyr311 phosphorylation of PKCδ in isolated islets.
(A) Isolated islets from 8 mice were homogenized in 20 mM Tris -HCl (pH 7.5) containing 100 mM NaCl, 0.5% Triton X-100, cOmplete Mini and
PhosSTOP. Whole cell lysates were prepared by sonication. Thirty μg of each protein sample was separated on a 10% SDS-PAGE gel and then
transferred onto a PVDF membrane. The membrane was briefly rinsed in Tris -buffered saline containing 0.1% Tween 20 (TBSt) and then incubated
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